Humasis said its board of directors decided to establish a U.S. subsidiary on Friday and started preparations.

In a public disclosure, Humasis said it would invest $2 million to complete the establishment of the U.S. offshoot by September.

Humasis will purchase new shares of the U.S. subsidiary 100 percent on Sept. 5.

“We will carry out the investment after obtaining approval of related organizations in Korea and the U.S.,” the company said.

Humasis plans to promote its diagnostic devices in the U.S. through its American subsidiary, as the U.S. diagnostics market is the world’s largest.

The company will focus on expanding the supply of Humasis COVID-19 Home Test, a Covid-19 self-test kit that obtained CE-Self testing from Health Canada on July 22 in North America.

“Through the U.S. subsidiary, we will promote active localization projects such as enhancing contact points with local clients,” an official at Humasis said. “We will also push for FDA approval for key products and raise brand awareness in the U.S., the largest diagnostics market.”